Abstract
e17553 Background: Rituximab has become the standard in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). The incremental cost of adding ritux...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have